Stockscreener 앱 받기
0.9486
16.19%
0.1322
시간 외 거래:
.95
0.0014
+0.15%
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Pharmaceuticals subsidiary reports 86% ORR, 57% CR with LYMPHIR prior to CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times
CTXR Should I Buy - Intellectia AI
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Citius Pharmaceuticals CEO Leonard Mazur pursues growth through regulatory partnerships and rare disease therapies - Traders Union
CTXR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Movement Recap: Is Citius Pharmaceuticals Inc benefiting from interest rate changesJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Citius Pharmaceuticals Secures $3.8M Via Net Operating Loss Program - New Jersey Business Magazine
Citius Pharmaceuticals (CTXR) Secures $3.8M Through NJ Tax Progr - GuruFocus
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PR Newswire
Market Pulse: Can Citius Pharmaceuticals Inc lead its sector in growthJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Resistance Check: Can GRNQ maintain sales growthWeekly Market Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Patterns Watch: Will USAC outperform small cap indexesWeekly Loss Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Activity Recap: How does USBPRA perform in inflationary periodsBull Run & Weekly Momentum Stock Picks - baoquankhu1.vn
Analyst Downgrade: Is NVGS forming bullish engulfing patternsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Leonard Mazur: The Adventures of a Serial Entrepreneur - Pharmaceutical Executive
Dip Buying: Will Citius Pharmaceuticals Inc benefit from rate cutsJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
CVI and Heights disclose 9.9% Citius Pharmaceuticals (CTXR) stake - Stock Titan
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com
FOMO Trade: Is now the right time to enter MAPSMarket Growth Summary & Weekly Momentum Picks - baoquankhu1.vn
Can Citius Pharmaceuticals Inc. stock continue upward trendWall Street Watch & Free High Return Stock Watch Alerts - mfd.ru
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt
Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal - Indian Pharma Post
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know - Benzinga
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk - TipRanks
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CTXR: First revenue of $3.9M from LYMPHIR launch, narrowing net loss and strong pipeline progress - TradingView
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Citius Pharmaceuticals reports first revenue of $3.9 mln - TradingView
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire
Risk Check: Should you buy the dip on ImmuCell CorporationWeekly Trend Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI
Market Review: Is Citius Pharmaceuticals Inc a cyclical or defensive stockPortfolio Performance Report & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long - simplywall.st
Does Citius Pharmaceuticals Inc. align with a passive investing strategyTrade Volume Report & Daily Technical Forecast Reports - mfd.ru
Aug PostEarnings: Is IMRN subject to activist investor interest2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz
Citius Oncology Expands International Distribution of LYMPHIR™ t - GuruFocus
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire
Is Citius Pharmaceuticals Inc. stock positioned well for digital economy2025 Performance Recap & Daily Entry Point Trade Alerts - mfd.ru
What is the earnings history of Citius Pharmaceuticals IncJuly 2025 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn
Risk Check: What is Citius Pharmaceuticals Incs 5 year growth outlookWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
VIX Spike: Is Citius Pharmaceuticals Inc a potential multi baggerJuly 2025 WrapUp & Smart Allocation Stock Tips - baoquankhu1.vn
Weekly Earnings: Can Howard Hughes Holdings Inc deliver consistent EPS growthEarnings Overview Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Citius Pharmaceuticals announces registered direct offering of $15.8 million - MSN
Geopolitics Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesTrade Performance Summary & Short-Term Trading Alerts - baoquankhu1.vn
What technical charts say about Citius Pharmaceuticals Inc. stock2025 Earnings Surprises & Weekly Top Stock Performers List - bollywoodhelpline.com
Setup Watch: Whats next for VGASW stock2025 Market Sentiment & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Published on: 2026-01-13 01:39:15 - ulpravda.ru
Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsEarnings Performance Report & Stepwise Trade Signal Implementation - ulpravda.ru
Will Citius Pharmaceuticals Inc. (47N0) stock outperform Dow Jones2025 Geopolitical Influence & Entry and Exit Point Strategies - Улправда
What hedge fund moves indicate for Citius Pharmaceuticals Inc. (47N0) stockShare Buyback & Stepwise Trade Signal Implementation - ulpravda.ru
Will Citius Pharmaceuticals Inc. stock continue upward momentumJuly 2025 Drop Watch & Technical Entry and Exit Alerts - Улправда
Is Citius Pharmaceuticals Inc. stock a top momentum playPortfolio Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
How Citius Pharmaceuticals Inc. (47N0) stock expands through international marketsMarket Growth Report & Consistent Profit Trade Alerts - Улправда
Can Citius Pharmaceuticals Inc. (47N0) stock resist broad market declinesJuly 2025 Big Picture & High Conviction Investment Ideas - Улправда
Will Citius Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Sentiment & Weekly Stock Breakout Alerts - ulpravda.ru
User | poteaudailynews.comCitius Pharmaceuticals, Inc.Common Stock (Nasdaq:CTXR) Stock Quote - FinancialContent
Portfolio Update: Can Citius Pharmaceuticals Inc 47N0 stock resist broad market declinesJuly 2025 Chart Watch & Safe Capital Allocation Plans - Bộ Nội Vụ
3.69%
0.68%
자본화:
|
볼륨(24시간):